Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 571

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 571
---
 reflecting the Acquisition Transactions to match that agreed to in the Merger Agreement, modify the allocation of the transaction consideration among the Target Companies to match that agreed to in the Merger Agreement, modify the minimum cash balance at closing of the Business Combination to match that agreed to in the Merger Agreement, and conform certain representations, warranties, covenants, closing conditions, termination provisions, and other provisions of the C&E Agreements to the Merger Agreement.

| F-49 |

longevity biomedical, inc.

notes to the financial statements (unaudited)

Second Amendment to the C&E Agreement

On June 26, 2023 the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to have a lock-up of 180 days for directors, officers and 5% or greater stockholders of the post-transaction company.

Third Amendment to the C&E Agreement

On August 29, 2023, the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to remove the minimum cash balance condition of $30 million.

Termination of C&E Agreement

On August 8, 2024, Longevity terminated the C&E Agreement with Novokera pursuant to Section 10.1(b) of the C&E Agreement due to multiple conditions not being satisfied or waived to close a business combination by October 25, 2023.

Fourth Amendment to the C&E Agreement

On August 8, 2024, the Company entered into amendments to the C&E Agreements with Aegeria and Cerevast (“Targets”) and each of the Targets’ respective shareholders and unitholders pursuant to which certain provisions of the C&E Agreements were amended to, among other things: modify the aggregate valuation assigned to Longevity reflecting a business combination and modify the allocation of the transaction consideration among the Targets and FutureTech Capital.

Note 8 - Subsequent Events

The Company has evaluated subsequent events in connection with the preparation of these financial statements, which is the date the financial statements were issued and determined that there were no significant unrecognized events through that date other than those noted below.

Promissory Notes

On October 31, 2024, the Company issued a $108,000 promissory note to FutureTech Capital. The promissory note is non-interest bearing and matures on April 30, 2025.

On November 4, 2024, the Company issued a $75,000 promissory note to FutureTech